2
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

QSAR With Electrotopological State Atom Index: Human Factor Xa Inhibitor N 2 -Aroylanthranilamides

, &
Pages 33-43 | Published online: 04 Dec 2011

References

  • Hammer, R. H. (1995). Anticoagulants, coagulants and plasma extenders. In Principles of Medicinal Chemistry, edited by W. O. Foye, T. L. Lemke, and D. A. Williams, New Delhi, India, B. I. Waverly Pvt. Ltd., pp. 388–404.
  • Majerus, P. W., Broze, G. J., Jr., Miletich, J. P., and Tollefsen, D. M. (1995). Anticoagulant, thrombolytic and antiplatelet drugs. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edited by J. G. Hardman and L E. Limbard, New York, McGraw-Hill., pp. 1341–1359.
  • Smyth, R. D., Perigard, C. P., and Smyth, R. J. (1995). Clinical analysis. In Remington: The Science and Practice of Pharmacy, edited by A. R. Gennaro, Pennsylvania: Mack Publishing Co., pp. 501–533.
  • Guyton, A. C. (1991). Textbook of Physiology, Bangalore, India, Prism Books Pvt. Ltd., pp. 390–399.
  • O'Niel, R. (1988) The blood. In Textbook of Physiology, edited by D. Emslie-Smith, C. R. Paterson, T. Scratcherd, and N. W. Read, Edinburgh: Churchill Livingstone, pp. 23–41.
  • Herron, D. K., Goodson, T., Jr., Wiley, M. R., Weir, L. C., Kyle, J. A., Yee, Y.K., Tebbe, A. L.,Tinsley, J. M., Mendel, D., Masters, J.J., Franciskovich, J.B., Sawyer, J.S., Beight, D.W., Ratz, A.M., Milot, G., Hall, S.E., Klimkowski, V. J., Wikel, J.H., Eastwood, B.J., Towner, R.D., Gifford-Moore, D.S., Craft, T.J., and Smith, G.F. (2000). 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J. Med. Chem., 43, 859–872.
  • Yee, Y. K., Tebbe, A. L., Linebarger, J. H., Beight, D. W., Craft, T. J., Gifford-Moore, D., Goodson, T., Jr., Herron, D. K., Klimkowski, V. J., Kyle, J. A., Sawyer, J. S., Smith, G. F., Tinsley, J. M., Towner, R. D., Weir, L., and Wiley, M. R. (2000). N 2-Aroylanthranilamide inhibitors of human factor Xa. J. Med. Chem., 43, 873–882.
  • Roy, K., De, A. U., and Sengupta, C. (2002). QSAR of human factor Xa inhibitor N 2-aroylanthranilamides using principal component factor analysis. Drug Des. Discov. 18, 23–31.
  • Hall, L. H., Mohney, B., and Kier, L. B. (1991). The electro-topological state: An atom index for QSAR. Quant. Struct.-Act. Relat., 10, 43–51.
  • Hall, L. H., Mohney, B., and Kier, L. B. (1993). Comparison of electrotopological state indexes with molecular orbital parameters: Inhibition of MAO by hydrazides. Quant. Struct.-Act. Relat., 12, 44–48.
  • Kier, L. B., and Hall, L. H. (1992). Atom description in QSAR models: Development and use of an atom level index. Adv. Drug Design, 22, 1–38.
  • The GW-BASIC programs ELECTROL, AUTOREG, AC, RRR98, KRPRES1, and KRPRES2 were developed by Kunal Roy (1998) and standardized on known data sets.
  • (a) Roy, K., De, A. U., and Sengupta, C. (1999). QSAR with electrotopological state atom index: Antiadrenergic activity of N, N-dimethyl-2-bromo-2-phenylethylamines. Indian J. Chem., 38B, 942-949. (b) Roy, K., Pal, D. K., Saha, A., and Sengupta, C. (2001). QSAR with electrotopological state atom index: Part II. Antimalarial activity of dihydroqinghaosu derivatives. Indian J. Chem., 40B, 587-595. (c) Saha, A., Roy, K., De, TABLE A1a Electrotopological states (SX) of the common atoms of N 2-aroylanthranilamides (part I) Atom nos. (x) K., and Sengupta, C. (2001). QSAR with electrotopological state atom index. Part 3. Receptor binding affinity of estrogens and non-steroidal estrogen analogs. J. Indian Chem. Soc., 78, 92–97. (d) Roy, K., Pal, D. K., and Sengupta, C. (2001). QSAR of antineoplastics. V: Exploration of receptor interaction sites of antitumor N -(7-Indolyl)benzenesulfonamides targeting G1 phase using electrotopological state atom index. Drug Design Discov., 17, 207–218.
  • Snedecor, G. W., and Cochran, W. G. (1967). Statistical Methods, New Delhi, India, Oxford & IBH Publishing Co. Pvt. Ltd., pp. 381–418.
  • Wold, S., and Errikson, L. (1995). Validation tools. In Chemo-metric Methods in Molecular Design, edited by H. van de Waterbeemd, Weinheim, Germany, VCH, pp. 309–318.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.